We report the complete genome sequence of BST19, an isolate from the allotment soil in Tainan, Taiwan. The genome was obtained using the PacBio Sequel II platform, yielding a circular chromosome of 4,167,147 bp with a 43.9% GC content.
View Article and Find Full Text PDFMyasthenia gravis (MG) stands as a prototypical antibody-mediated autoimmune disease: it is dependent on T cells and characterized by the presence of autoantibodies targeting proteins located on the postsynaptic surface of skeletal muscle, known as the neuromuscular junction. Patients with MG exhibit a spectrum of weakness, ranging from limited ocular muscle involvement to life-threatening respiratory failure. Recent decades have witnessed substantial progress in understanding the underlying pathophysiology, leading to the delineation of distinct subcategories within MG, including MG linked to AChR or MuSK antibodies as well as age-based distinction, thymoma-associated, and immune checkpoint inhibitor-induced MG.
View Article and Find Full Text PDFContamination with traces of pharmaceutical compounds, such as ciprofloxacin, has prompted interest in their removal via low-cost, efficient biomass-based adsorption. In this study, classical models, a mechanistic model, and a neural network model were evaluated for predicting ciprofloxacin breakthrough curves in both laboratory- and pilot scales. For the laboratory-scale (d = 2.
View Article and Find Full Text PDFJ Clin Neuromuscul Dis
June 2022
We present the case of a 37-year-old woman with alcohol use disorder, who developed leg cramping, bilateral foot drop, and hand weakness 3 months after starting disulfiram. This was accompanied by an 18-pound involuntary weight loss. Electrophysiologic findings showed a motor predominant axonal neuropathy.
View Article and Find Full Text PDFBackground: The cost-effectiveness of community health worker (CHW)-based cardiovascular disease (CVD) risk-reduction interventions is not well established. Colorado Heart Healthy Solutions is a CHW-based intervention designed to reduce modifiable CVD risk factors. This program has previously demonstrated success, but the cost-effectiveness is unknown.
View Article and Find Full Text PDF